Hema Now
In this episode of Hema Now, John Maher reflects on more than 2 decades at the forefront of CAR-T cell research. He discusses the major milestones that have transformed CAR-T therapy into a clinical reality, the biological barriers that continue to limit success in solid tumours, and the next-generation engineering approaches being developed to enhance efficacy and safety. Maher also shares insights into the origins of the CAR Mechanics Group, the challenge of overcoming the tumour microenvironment, and his vision for the future of cellular immunotherapy.
Spotify | Apple | Amazon Music | YouTube | Download MP3
In this episode of Hema Now, John Maher reflects on more than 2 decades at the forefront of CAR-T cell research. He discusses the major milestones that have transformed CAR-T therapy into a clinical reality, the biological barriers that continue to limit success in solid tumours, and the next-generation engineering approaches being developed to enhance efficacy and safety. Maher also shares insights into the origins of the CAR Mechanics Group, the challenge of overcoming the tumour microenvironment, and his vision for the future of cellular immunotherapy.
Timestamps:
00:00 – Introduction
01:07 – Career Journey into Immunotherapy
02:22 – Key CAR-T Therapy Milestones
05:50 – Overcoming Solid Tumour Barriers
09:14 – Origins of CAR Mechanics
12:35 – Most Exciting Current Innovations
16:08 – Improving CAR-T Safety Profiles
20:07 – Challenges of Tumour Microenvironments
23:04 – Future of Cellular Immunotherapy
27:15 – Three Magic Wishes
Disclaimer: The opinions expressed in this episode belong to the speakers and do not necessarily represent the opinions of EMJ.
Keywords: Adoptive cell therapy, cancer immunotherapy, CAR Mechanics Group, CAR-T therapy, cellular immunotherapy, haematology, mucin 1 (MUC1), oncology, solid tumours, T cell engineering, translational research, tumour microenvironment.
